GILD
HealthcareGilead Sciences, Inc.
$144.25-0.96 (-0.66%)
Prev Close
$145.21
Open
$146.85
High
$148.22
Low
$144.24
Volume
2.58M
Market Cap
$180.27B
P/E
21.31
Div Yield
0.02%
Over the past 12 months, insider activity at Gilead Sciences, Inc. (GILD) has been exclusively selling, with 0 insider purchases totaling $0.00 and 27 insider sales totaling $60.44M. The most recent insider transaction was by O'Day Daniel Patrick (director, officer: Chairman & CEO), who sold $1.45M worth of shares on Mar 2, 2026. Gilead Sciences, Inc. operates in the Healthcare sector, within the Drug Manufacturers - General industry, with a market cap of $180.27B.
Buys (12M)
0
$0.00
Sells (12M)
27
$60.44M
Net Activity
Net Seller
$60.44M
Active Insiders
7
last 12 mo
GILD Price Chart
GILD Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 2, 2026↗ | O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 10,000 | $144.79 | $1.45M | 648,827 |
| Feb 18, 2026↗ | Dickinson Andrew D | officer: Chief Financial Officer | Sell | 3,000 | $154.43 | $463.3K | 167,779 |
| Feb 18, 2026↗ | Mercier Johanna | officer: Chief Comm & Corp Aff Officer | Sell | 28,000 | $154.44 | $4.32M | 129,883 |
| Feb 17, 2026↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 3,000 | $154.43 | $463.3K | 0 |
| Feb 17, 2026↗ | Mercier Johanna | Chief Comm & Corp Aff Officer | Sell | 28,000 | $154.44 | $4.32M | 0 |
| Feb 6, 2026↗ | O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 115,640 | $150.00 | $17.35M | 613,912 |
| Jan 29, 2026↗ | O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 20,000 | $139.89 | $2.80M | 561,666 |
| Jan 26, 2026↗ | O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 115,640 | $135.00 | $15.61M | 566,698 |
| Jan 21, 2026↗ | Bluestone Jeffrey | Director | Sell | 10,000 | $123.50 | $1.24M | 8,920 |
| Jan 16, 2026↗ | Dickinson Andrew D | officer: Chief Financial Officer | Sell | 6,000 | $124.31 | $745.9K | 150,503 |
| Jan 16, 2026↗ | Mercier Johanna | officer: Chief Commercial Officer | Sell | 3,000 | $124.31 | $372.9K | 103,221 |
| Jan 5, 2026↗ | Berger Dietmar | Chief Medical Officer | Sell | 6,944 | $121.60 | $844.4K | 0 |
| Dec 11, 2025↗ | O'Day Daniel Patrick | Chairman & CEO | Sell | 4,931 | $121.34 | $598.3K | 0 |
| Dec 1, 2025↗ | Bluestone Jeffrey | Director | Sell | 5,000 | $125.08 | $625.4K | 0 |
| Dec 1, 2025↗ | O'Day Daniel Patrick | Chairman & CEO | Sell | 10,000 | $126.54 | $1.27M | 0 |
| Nov 18, 2025↗ | Mercier Johanna | Chief Commercial Officer | Sell | 28,000 | $125.86 | $3.52M | 0 |
| Oct 27, 2025↗ | Telman Deborah H | EVP, Corporate Affairs & GC | Sell | 241 | $120.94 | $29.1K | 0 |
| Oct 16, 2025↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 2,500 | $118.08 | $295.2K | 0 |
| Sep 16, 2025↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 2,500 | $113.57 | $283.9K | 0 |
| Sep 11, 2025↗ | Mercier Johanna | Chief Commercial Officer | Sell | 1,819 | $115.25 | $209.6K | 0 |
| Sep 11, 2025↗ | Wilfong Diane E. | Interim Corp Controller & CAO | Sell | 338 | $115.25 | $39.0K | 0 |
| Aug 29, 2025↗ | O'Day Daniel Patrick | Chairman & CEO | Sell | 10,000 | $113.63 | $1.14M | 0 |
| Aug 18, 2025↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 2,500 | $118.53 | $296.3K | 0 |
| Jul 28, 2025↗ | Telman Deborah H | EVP, Corporate Affairs & GC | Sell | 3,823 | $116.20 | $444.2K | 0 |
| Jul 16, 2025↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 2,500 | $111.03 | $277.6K | 0 |
| Jul 1, 2025↗ | O'Day Daniel Patrick | Chairman & CEO | Sell | 10,000 | $110.45 | $1.10M | 0 |
| Jun 17, 2025↗ | Mercier Johanna | Chief Commercial Officer | Sell | 3,000 | $110.17 | $330.5K | 0 |
| Mar 12, 2025↗ | Mercier Johanna | Chief Commercial Officer | Sell | 3,907 | $117.21 | $457.9K | 0 |
| Feb 19, 2025↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 2,500 | $104.09 | $260.2K | 0 |
| Feb 6, 2025↗ | O'Day Daniel Patrick | Chairman & CEO | Sell | 108,156 | $97.99 | $10.60M | 0 |
| Feb 3, 2025↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 142,180 | $97.22 | $13.82M | 129,873 |
| Jan 16, 2025↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 2,500 | $91.35 | $228.4K | 129,873 |
| Dec 23, 2024↗ | GILEAD SCIENCES, INC. | 10% Owner | Buy | 940,499 | $21.37 | $20.10M | 2,209,470 |
| Dec 19, 2024↗ | GILEAD SCIENCES, INC. | 10% Owner | Buy | 1,759,978 | $1.04 | $1.83M | 9,105,450 |
| Dec 17, 2024↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 8,500 | $91.96 | $781.7K | 132,373 |
| Dec 3, 2024↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 248,645 | $92.76 | $23.07M | 266,849 |
| Nov 29, 2024↗ | Parsey Merdad | Chief Medical Officer | Sell | 164,211 | $91.92 | $15.09M | 187,718 |
| Nov 27, 2024↗ | Bluestone Jeffrey | Director | Sell | 6,788 | $91.39 | $620.4K | 8,920 |
| Nov 7, 2024↗ | Mercier Johanna | Chief Commercial Officer | Sell | 5,000 | $91.28 | $456.4K | 73,127 |
| Nov 7, 2024↗ | Parsey Merdad | Chief Medical Officer | Sell | 25,590 | $91.50 | $2.34M | 104,599 |
| Oct 2, 2024↗ | Parsey Merdad | Chief Medical Officer | Sell | 2,000 | $83.83 | $167.7K | 100,189 |
| Sep 13, 2024↗ | Mercier Johanna | Chief Commercial Officer | Sell | 29,357 | $83.78 | $2.46M | 91,559 |
| Sep 13, 2024↗ | Parsey Merdad | Chief Medical Officer | Sell | 21,246 | $84.50 | $1.80M | 102,189 |
| Aug 29, 2024↗ | Mercier Johanna | Chief Commercial Officer | Sell | 9,513 | $78.03 | $742.3K | 105,466 |
| Aug 14, 2024↗ | Mercier Johanna | Chief Commercial Officer | Sell | 5,490 | $73.98 | $406.1K | 114,979 |
| Jul 1, 2024↗ | Parsey Merdad | Chief Medical Officer | Sell | 2,000 | $68.63 | $137.3K | 96,380 |
| Apr 3, 2024↗ | GILEAD SCIENCES, INC. | 10% Owner | Buy | 485,250 | $0.76 | $368.8K | 7,345,470 |
| Apr 2, 2024↗ | Parsey Merdad | Chief Medical Officer | Sell | 2,000 | $72.96 | $145.9K | 96,304 |
| Feb 29, 2024↗ | Parsey Merdad | Chief Medical Officer | Sell | 10,230 | $72.82 | $745.0K | 100,936 |
| Feb 13, 2024↗ | GILEAD SCIENCES, INC. | 10% Owner | Buy | 910,000 | $22.00 | $20.02M | 4,126,120 |
| Jan 31, 2024↗ | GILEAD SCIENCES, INC. | 10% Owner | Buy | 15,238,095 | $21.00 | $320.00M | 30,061,100 |
| Jan 17, 2024↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 5,000 | $85.78 | $428.9K | 101,534 |
| Jan 10, 2024↗ | Mercier Johanna | Chief Commercial Officer | Sell | 8,242 | $85.23 | $702.5K | 82,729 |
| Oct 18, 2023↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 5,000 | $80.00 | $400.0K | 104,003 |
| Sep 13, 2023↗ | Parsey Merdad | Chief Medical Officer | Sell | 1,501 | $76.99 | $115.6K | 70,130 |
| Jul 21, 2023↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 5,000 | $80.00 | $400.0K | 107,587 |
| Jun 30, 2023↗ | GILEAD SCIENCES, INC. | 10% Owner | Buy | 1,010,000 | $19.26 | $19.45M | 14,823,000 |
| Jun 28, 2023↗ | GILEAD SCIENCES, INC. | 10% Owner | Buy | 2,930,870 | $3.75 | $10.99M | 16,635,300 |
| Jun 14, 2023↗ | Parsey Merdad | Chief Medical Officer | Sell | 1,485 | $76.90 | $114.2K | 29,402 |
| Mar 14, 2023↗ | Parsey Merdad | Chief Medical Officer | Sell | 6,126 | $78.99 | $483.9K | 70,130 |
| Mar 2, 2023↗ | Parsey Merdad | Chief Medical Officer | Sell | 12,984 | $79.96 | $1.04M | 70,130 |
| Jan 3, 2023↗ | Parsey Merdad | Chief Medical Officer | Sell | 553 | $85.33 | $47.2K | 45,556 |
GILD Insider Buying Activity
The following table shows recent insider purchases of Gilead Sciences, Inc. (GILD) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Dec 23, 2024↗ | GILEAD SCIENCES, INC. | 10% Owner | Buy | 940,499 | $21.37 | $20.10M | 2,209,470 |
| Dec 19, 2024↗ | GILEAD SCIENCES, INC. | 10% Owner | Buy | 1,759,978 | $1.04 | $1.83M | 9,105,450 |
| Apr 3, 2024↗ | GILEAD SCIENCES, INC. | 10% Owner | Buy | 485,250 | $0.76 | $368.8K | 7,345,470 |
| Feb 13, 2024↗ | GILEAD SCIENCES, INC. | 10% Owner | Buy | 910,000 | $22.00 | $20.02M | 4,126,120 |
| Jan 31, 2024↗ | GILEAD SCIENCES, INC. | 10% Owner | Buy | 15,238,095 | $21.00 | $320.00M | 30,061,100 |
| Jun 30, 2023↗ | GILEAD SCIENCES, INC. | 10% Owner | Buy | 1,010,000 | $19.26 | $19.45M | 14,823,000 |
| Jun 28, 2023↗ | GILEAD SCIENCES, INC. | 10% Owner | Buy | 2,930,870 | $3.75 | $10.99M | 16,635,300 |
GILD Insider Selling Activity
The following table shows recent insider sales of Gilead Sciences, Inc. (GILD) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 2, 2026↗ | O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 10,000 | $144.79 | $1.45M | 648,827 |
| Feb 18, 2026↗ | Dickinson Andrew D | officer: Chief Financial Officer | Sell | 3,000 | $154.43 | $463.3K | 167,779 |
| Feb 18, 2026↗ | Mercier Johanna | officer: Chief Comm & Corp Aff Officer | Sell | 28,000 | $154.44 | $4.32M | 129,883 |
| Feb 17, 2026↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 3,000 | $154.43 | $463.3K | 0 |
| Feb 17, 2026↗ | Mercier Johanna | Chief Comm & Corp Aff Officer | Sell | 28,000 | $154.44 | $4.32M | 0 |
| Feb 6, 2026↗ | O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 115,640 | $150.00 | $17.35M | 613,912 |
| Jan 29, 2026↗ | O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 20,000 | $139.89 | $2.80M | 561,666 |
| Jan 26, 2026↗ | O'Day Daniel Patrick | director, officer: Chairman & CEO | Sell | 115,640 | $135.00 | $15.61M | 566,698 |
| Jan 21, 2026↗ | Bluestone Jeffrey | Director | Sell | 10,000 | $123.50 | $1.24M | 8,920 |
| Jan 16, 2026↗ | Dickinson Andrew D | officer: Chief Financial Officer | Sell | 6,000 | $124.31 | $745.9K | 150,503 |
| Jan 16, 2026↗ | Mercier Johanna | officer: Chief Commercial Officer | Sell | 3,000 | $124.31 | $372.9K | 103,221 |
| Jan 5, 2026↗ | Berger Dietmar | Chief Medical Officer | Sell | 6,944 | $121.60 | $844.4K | 0 |
| Dec 11, 2025↗ | O'Day Daniel Patrick | Chairman & CEO | Sell | 4,931 | $121.34 | $598.3K | 0 |
| Dec 1, 2025↗ | Bluestone Jeffrey | Director | Sell | 5,000 | $125.08 | $625.4K | 0 |
| Dec 1, 2025↗ | O'Day Daniel Patrick | Chairman & CEO | Sell | 10,000 | $126.54 | $1.27M | 0 |
| Nov 18, 2025↗ | Mercier Johanna | Chief Commercial Officer | Sell | 28,000 | $125.86 | $3.52M | 0 |
| Oct 27, 2025↗ | Telman Deborah H | EVP, Corporate Affairs & GC | Sell | 241 | $120.94 | $29.1K | 0 |
| Oct 16, 2025↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 2,500 | $118.08 | $295.2K | 0 |
| Sep 16, 2025↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 2,500 | $113.57 | $283.9K | 0 |
| Sep 11, 2025↗ | Mercier Johanna | Chief Commercial Officer | Sell | 1,819 | $115.25 | $209.6K | 0 |
| Sep 11, 2025↗ | Wilfong Diane E. | Interim Corp Controller & CAO | Sell | 338 | $115.25 | $39.0K | 0 |
| Aug 29, 2025↗ | O'Day Daniel Patrick | Chairman & CEO | Sell | 10,000 | $113.63 | $1.14M | 0 |
| Aug 18, 2025↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 2,500 | $118.53 | $296.3K | 0 |
| Jul 28, 2025↗ | Telman Deborah H | EVP, Corporate Affairs & GC | Sell | 3,823 | $116.20 | $444.2K | 0 |
| Jul 16, 2025↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 2,500 | $111.03 | $277.6K | 0 |
| Jul 1, 2025↗ | O'Day Daniel Patrick | Chairman & CEO | Sell | 10,000 | $110.45 | $1.10M | 0 |
| Jun 17, 2025↗ | Mercier Johanna | Chief Commercial Officer | Sell | 3,000 | $110.17 | $330.5K | 0 |
| Mar 12, 2025↗ | Mercier Johanna | Chief Commercial Officer | Sell | 3,907 | $117.21 | $457.9K | 0 |
| Feb 19, 2025↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 2,500 | $104.09 | $260.2K | 0 |
| Feb 6, 2025↗ | O'Day Daniel Patrick | Chairman & CEO | Sell | 108,156 | $97.99 | $10.60M | 0 |
| Feb 3, 2025↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 142,180 | $97.22 | $13.82M | 129,873 |
| Jan 16, 2025↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 2,500 | $91.35 | $228.4K | 129,873 |
| Dec 17, 2024↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 8,500 | $91.96 | $781.7K | 132,373 |
| Dec 3, 2024↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 248,645 | $92.76 | $23.07M | 266,849 |
| Nov 29, 2024↗ | Parsey Merdad | Chief Medical Officer | Sell | 164,211 | $91.92 | $15.09M | 187,718 |
| Nov 27, 2024↗ | Bluestone Jeffrey | Director | Sell | 6,788 | $91.39 | $620.4K | 8,920 |
| Nov 7, 2024↗ | Mercier Johanna | Chief Commercial Officer | Sell | 5,000 | $91.28 | $456.4K | 73,127 |
| Nov 7, 2024↗ | Parsey Merdad | Chief Medical Officer | Sell | 25,590 | $91.50 | $2.34M | 104,599 |
| Oct 2, 2024↗ | Parsey Merdad | Chief Medical Officer | Sell | 2,000 | $83.83 | $167.7K | 100,189 |
| Sep 13, 2024↗ | Mercier Johanna | Chief Commercial Officer | Sell | 29,357 | $83.78 | $2.46M | 91,559 |
| Sep 13, 2024↗ | Parsey Merdad | Chief Medical Officer | Sell | 21,246 | $84.50 | $1.80M | 102,189 |
| Aug 29, 2024↗ | Mercier Johanna | Chief Commercial Officer | Sell | 9,513 | $78.03 | $742.3K | 105,466 |
| Aug 14, 2024↗ | Mercier Johanna | Chief Commercial Officer | Sell | 5,490 | $73.98 | $406.1K | 114,979 |
| Jul 1, 2024↗ | Parsey Merdad | Chief Medical Officer | Sell | 2,000 | $68.63 | $137.3K | 96,380 |
| Apr 2, 2024↗ | Parsey Merdad | Chief Medical Officer | Sell | 2,000 | $72.96 | $145.9K | 96,304 |
| Feb 29, 2024↗ | Parsey Merdad | Chief Medical Officer | Sell | 10,230 | $72.82 | $745.0K | 100,936 |
| Jan 17, 2024↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 5,000 | $85.78 | $428.9K | 101,534 |
| Jan 10, 2024↗ | Mercier Johanna | Chief Commercial Officer | Sell | 8,242 | $85.23 | $702.5K | 82,729 |
| Oct 18, 2023↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 5,000 | $80.00 | $400.0K | 104,003 |
| Sep 13, 2023↗ | Parsey Merdad | Chief Medical Officer | Sell | 1,501 | $76.99 | $115.6K | 70,130 |
| Jul 21, 2023↗ | Dickinson Andrew D | Chief Financial Officer | Sell | 5,000 | $80.00 | $400.0K | 107,587 |
| Jun 14, 2023↗ | Parsey Merdad | Chief Medical Officer | Sell | 1,485 | $76.90 | $114.2K | 29,402 |
| Mar 14, 2023↗ | Parsey Merdad | Chief Medical Officer | Sell | 6,126 | $78.99 | $483.9K | 70,130 |
| Mar 2, 2023↗ | Parsey Merdad | Chief Medical Officer | Sell | 12,984 | $79.96 | $1.04M | 70,130 |
| Jan 3, 2023↗ | Parsey Merdad | Chief Medical Officer | Sell | 553 | $85.33 | $47.2K | 45,556 |
GILD Insiders
Similar Stocks to GILD
LLY
Eli Lilly and Company
$984.11+0.70%
$921.90B
JNJ
Johnson & Johnson
$241.86-0.07%
$583.29B
ABBV
AbbVie Inc.
$220.81-2.02%
$398.49B
MRK
Merck & Co., Inc.
$115.92+0.00%
$286.57B
AMGN
Amgen Inc.
$366.74-0.29%
$198.26B
PFE
Pfizer Inc.
$26.62-0.89%
$152.73B
BMY
Bristol-Myers Squibb Company
$58.93-0.04%
$120.05B
BIIB
Biogen Inc.
$183.58-0.71%
$27.14B